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ABSTRACT
Hepatocellular carcinoma is one of the major cancer problems in the world because of the low early screening 
awareness in patients. Serum alpha-fetoprotein is not adequate as a single screening tool, especially for small HCCs, 
thus, prothrombin induced by vitamin K absence-II (PIVKA-II) can help in detecting small HCCs. Barcelona Clinic 
Liver Cancer (BCLC) stage remains to be the preferred HCC classification because it can predict the outcome and help 
in choosing available treatment options according to stages. This study aims to investigate the association between 
PIVKA-II levels with BCLC stage, tumor size, portal venous thrombosis in HCC patients. We enrolled patients with newly 
diagnosed HCC at the Adam Malik General Hospital, Medan, Indonesia from January to December 2018. Patients 
with HCC were classified according to BCLC stages, findings of portal venous thrombosis and tumor size from triphasic 
CT scan were noted, and serum PIVKA-II levels were measured. Sixty patients were included in this study. There were 
significant differences in serum PIVKA-II levels with different stages of BCLC (p < 0.001). Significantly higher serum 
PIVKA-II levels were detected in patients with portal venous thrombosis (p < 0.001) and larger size tumors (p < 0.003). 
Our study shows that serum PIVKA-II levels can help to diagnose, differentiate between stages of BCLC, and determine 
the prognosis in patients with HCC. 
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ABSTRAK
Karsinoma hepatosel adalah salah satu masalah kanser utama di dunia kerana kesedaran awal yang rendah dalam 
kalangan pesakit. Serum alfa-fetoprotein tidak mencukupi sebagai alat pemeriksaan tunggal, terutamanya untuk HCCs 
kecil, oleh itu protrombin yang disebabkan oleh ketiadaan vitamin K II (PIVKA-II) dapat membantu dalam mengesan 
HCCs kecil. Tahap Kanser Hati Klinik Barcelona (BCLC) tetap menjadi pilihan dalam pengelasan HCC kerana dapat 
meramalkan hasil dan membantu dalam memilih pilihan rawatan yang tersedia mengikut tahap. Kajian ini bertujuan 
untuk mengkaji hubungan antara tahap PIVKA-II dengan peringkat BCLC, saiz tumor, trombosis vena portal pada 
pesakit HCC. Kami mendaftarkan pesakit dengan HCC yang baru didiagnosis di Hospital Besar Adam Malik, Medan, 
Indonesia sepanjang tempoh Januari hingga Disember 2018. Pesakit dengan HCC dikelaskan mengikut tahap BCLC, 
penemuan trombosis vena portal dan saiz tumor daripada imbasan CT triphasic dicatat dan paras serum PIVKA-II 
dihitung. Enam puluh pesakit dimasukkan ke dalam kajian ini. Terdapat perbezaan yang signifikan antara paras serum 
PIVKA-II dengan peringkat BCLC yang berlainan (p < 0.001). Tahap serum PIVKA-II yang lebih tinggi dikesan pada 
pesakit dengan trombosis vena portal (p < 0.001) dan tumor saiz yang lebih besar (p < 0.003). Kajian kami menunjukkan 
bahawa tahap serum PIVKA-II boleh membantu untuk mendiagnosis, membezakan antara peringkat BCLC dan 
menentukan prognosis pada pesakit dengan HCC.
Kata kunci: Hepatoma; karsinoma hepatosel; karsinoma sel hati; penanda biologi tumor 
INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the major 
cancer problems in the world (Tang et al. 2018). Usually 
asymptomatic in the early stage, it causes high mortality 
because of the low awareness in early screening from the 
patient (He et al. 2013). Challenges in clinical practice 
diagnosis of HCC often precludes early treatment, thus, 
reducing the survival rate (Pazgan-Simon et al. 2015). Some 
serum biomarkers are introduced to detect HCC at early 
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stages, such as alpha-fetoprotein (AFP) and prothrombin 
induced by vitamin K absence-II (PIVKA-II), also known 
as des-γ-carboxyl prothrombin (DCP) (Chen et al. 2018).
Serum AFP, which has been widely used for the 
screening of HCC, is not an adequate single screening 
tool, especially for small HCCs (Carr et al. 2018), thus, 
it is important to find new non-AFP markers for early 
diagnosis. Prothrombin induced by vitamin K absence-II 
(PIVKA-II), also known as des-γ-carboxyl prothrombin 
(DCP) has been linked to HCC especially in the early stages 
compared with non-HCC, especially hepatitis B virus 
(HBV) related HCC (Wang et al. 2017). It is released in 
the absence of vitamin K or when its action is antagonized 
by vitamin K antagonists (warfarin) (Zhang et al. 2014). 
In patients with HCC, there is impairment of vitamin 
K uptake which causes the production of PIVKA-II, 
aggravated by unfavorable microenvironments such as 
hypoxia (Murata et al. 2010).
Over the years, some methods have been developed 
to classify the severity of HCC, but Barcelona Clinic 
Liver Cancer (BCLC) staging remains to be preferred 
because it can predict the outcome and help in planning 
treatment options depending on the stages (Saraswat et 
al. 2014). However, BCLC staging itself is not perfect, 
moreover in stage B (intermediate stage) which has a 
heterogeneous population with varying degree of severity, 
thus preventing determination of optimal treatment option 
and resulting in heterogeneity of prognosis (Bolondi et al. 
2012; Farinati et al. 2015; Kinoshita et al. 2015).
Therefore, to help diagnose and further determine 
the best treatment option and prognosis for patients with 
HCC, this study aims to investigate the association between 
serum PIVKA-II levels with BCLC stage, tumor size, portal 
venous thrombosis in HCC patients.
MATERIALS AND METHODS
This cross-sectional study included a minimum of 54 
patients with newly diagnosed HCC, all of which were 
presented at outpatients’ clinic or emergency unit at 
the Adam Malik General Hospital, Medan, Indonesia 
from January to December 2018. The diagnosis of 
HCC was confirmed by a triphasic CT scan (arterial 
hypervascularity followed by venous and/or delayed phase 
‘washout’) (Pang et al. 2019). Findings of portal venous 
thrombosis and tumor size were noted. The presence or 
absence of portal venous thrombosis was noted. Tumor size 
was classified into less than 3, 3 to 5, and more than 5 cm.
Patients with cholangiocarcinoma, hemangioma, and 
liver metastasis were excluded from the study. Informed 
consent and approval from all patients were obtained after 
sufficient information was given about the study before 
enrollment. The study was approved by the Institutional 
Review Board of Universitas Sumatera Utara No. 417/
TGL/KEPK FK USU-RSUP HAM/2017.
Patients with HCC were classified according to 
Barcelona Clinic Liver Cancer (BCLC) classification to 
early-stage HCC (stage A), intermediate stage HCC (stage 
B), advanced stage (stage C), and terminal stage (stage 
D) based on tumor extension, liver functional reserve, 
physical status, and cancer-related symptoms (Kinoshita 
et al. 2015). Three milliliters of blood samples were 
collected from antecubital vein following proper aseptic 
procedures into EDTA tube, then stored at two to eight 
degrees Celsius. All samples were centrifuged for 15 min 
to obtain serum then stored at minus twenty degrees Celsius 
before subjected to measure PIVKA-II level using PIVKA-
II kit (Stago Diagnostica, France) by ELISA technique 
(Zakhary et al. 2013).
Statistical analysis was performed using SPSS 
22.0 software (IBM Corp., Armonk, NY, USA). The 
distribution of serum PIVKA-II levels was analyzed using 
the Kolmogorov-Smirnov test. A comparison of serum 
PIVKA-II levels between two groups was done using an 
independent sample t-test if the distribution of serum 
PIVKA-II levels was normal, Mann-Whitney U test was 
used otherwise. One-way ANOVA was used to compare 
the serum PIVKA-II levels between more than 2 groups 
if the distribution was normal, Kruskal-Wallis test was 
used if the distribution was not normal, then serial Mann-
Whitney U tests were used for pair-wise comparison. 
P-value of < 0.05 was considered significant.
 RESULTS AND DISCUSSION
A total of 60 subjects were enrolled in this study. The 
mean age for subjects was 61.4 (SD 11.7) years. Male 
subjects were dominant (78.3%). More than half of the 
subjects had Hepatitis B infection as the etiology of 
hepatocellular carcinoma. Based on BCLC staging, 25 
(41.7%) subjects were in stage C. Most subjects had 
portal venous thrombosis and tumors with a diameter of 
>5 cm. The median PIVKA-II level in this study was 
149.5 ng/mL. Subjects’ characteristics distribution was 
shown in Table 1.
There were significant differences in serum PIVKA-II 
levels in patients with different stages of BCLC (Figure 
1). Serum PIVKA-II levels were significantly higher (P 
=0.002) in patients with BCLC stage B compared with 
patients with BCLC stage A. Similar results were obtained 
when serum PIVKA-II levels of patients with BCLC stage 
A were compared with patients with BCLC stage C and 
D (P <0.001 and P <0.001, respectively). There were also 
significant differences in serum PIVKA-II levels of patients 
with BCLC stage B compared with patients with BCLC 
stage C and D (P =0.006 and P =0.028, respectively). 
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Serum PIVKA-II levels were not different between patients 
with BCLC stage C and D (P =0.759).
Some of the prognostic factors of HCC (portal venous 
thrombosis and tumor size) were compared (Table 2) 
and significantly higher serum of PIVKA-II levels was 
detected in patients with portal venous thrombosis (P = 
0.001) and larger size tumor (P = 0.003). There were no 
significant differences when comparing tumor size less 
than 3 and 3-5 cm (P =0.199).
TABLE 1. Characteristics of hepatocellular carcinoma patients
Characteristic n = 60
Mean age, years (SD) 61.4 (11.7)
Sex, n (%)
     Male




     Hepatitis B
     Hepatitis C




BCLC stages, n (%)
     Stage A
     Stage B
     Stage C





Portal venous thrombosis, n (%)
     Present
     Absent
33 (55.0)
27 (45.0)
Tumor size, n (%)
     < 3 cm
     3 - 5 cm




Median PIVKA-II levels, ng/mL (min-max) 149.5 (29 - 204)
TABLE 2. Serum prothrombin induced vitamin K absence-II (PIVKA-II) levels of hepatocellular carcinoma patients with 
different prognostic factors
PIVKA-II levels (ng/mL) P
Portal venous thrombosis
     Present 168 (52 - 204)
0.001a
     Absent 89 (29 - 187)
Tumor size
     < 3 cm 58 (35 - 175) 0.005b
     3-5 cm 135.5 (29 - 200) 0.006b
     > 5 cm 176 (79 - 204) ---
























Prothrombin induced by vitamin K absence-II (PIVKA-II) levels of 
hepatocellular carcinoma (HCC) patients according to BCLC
FIGURE 1. Prothrombin induced by vitamin K absence-II (PIVKA-II) levels of 
hepatocellular carcinoma (HCC) patients according to Barcelona Clinic 
Liver Cancer (BCLC) classification. *p-value < 0.05
Liver cancer is one of the most common cancer and 
the leading cause of cancer death in the world (Tang et 
al. 2018). Liver cancer, especially HCC can be classified 
by using BCLC classification which is used to guide the 
treatment allocation for each stage of BCLC (Saraswat et 
al. 2014). The adherence to BCLC treatment allocation 
recommendation in clinical practice varies according 
to the stages, but it positively impacts the survival rate, 
moreover in patients with BCLC stage A (Kikuchi et al. 
2017), thus HCC needs to be diagnosed early (Yu et al. 
2016). In this study, the patients were treated according 
to their BCLC classification. Patients in stage A BCLC 
underwent liver resection in one patient, radiofrequency 
ablation in two patients, and the other two patients refused 
any kind of treatment modalities. All patients Stage 
B BCLC underwent trans-arterial chemoembolization 
(TACE), whereas all patients in stage C BCLC were treated 
with sorafenib. Best supportive care was chosen by all 
patients in stage D BCLC.
The results of the treatment and prognosis of the 
patients however are within the limitation of the current 
study.
This study showed that there was a higher male 
proportion of HCC patients. This finding is consistent with 
studies by Liu et al. (2017) and Wu et al. (2018), although 
a study by Zhang et al. (2019) stated the reduced male-
to-female incidence rate ratio among persons aged less 
than 50 years old. Male predominance is more likely to 
be caused by hormonal differences between males and 
females, specifically premenopausal females (Keng et al. 
2012; Li et al. 2017). 
Compared with alpha-fetoprotein (AFP), it is known 
that PIVKA-II is superior in early diagnosis (Ma et al. 
2018; Svobodova et al. 2018; Wu et al. 2018), because of 
the gradual increase in serum PIVKA-II levels according 
to stages and the severity of HCC (Yu et al. 2017; Zakhary 
et al. 2013). This is consistent with the result of this study 
which showed higher serum PIVKA-II levels in patients 
with portal venous thrombosis, tumor size more than 5 
cm, and higher stages of BCLC but not between stage 
C and stage D BCLC. Increasing serum PIVKA-II levels 
were associated with progression and oncogenesis 
of HCC (Yu et al. 2017), whereas BCLC were used for 
predicting the prognosis of the patients, based not only 
on the severity of liver damage and tumor stage but also 
based on the performance status of the patients (Pons et al. 
2005). This finding might show there was no difference in 
the progression of HCC in stage C compared to stage D 
BCLC, but there might be changes in the prognosis of the 
patient due to performance status.
This study showed that there were differences in 
serum PIVKA-II levels of patients with BCLC stage B 
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compared with stage C and stage D. According to BCLC 
treatment allocation, it is recommended to treat stage B 
BCLC with TACE (Marrero et al. 2018), however, a study 
by Farinati et al. (2015) stated that TACE could not be 
considered as the best treatment option for BCLC stage 
B in clinical practice. Another study by Zhaohui et al. 
(2018) concluded that patients with stage B1 according 
to Bolondi’s subclassification (Bolondi et al. 2012) 
benefited from hepatic resection and had comparable 
survival rate with BCLC stage A patients. Studies by 
Kamiyama et al. (2017, 2015) showed that hepatectomy 
could be considered in BCLC stage B HCC patients with 
tumor number less than 4 and/or AP-factor (AFP × PIVKA-
II) less than 1 × 105.
There were some limitations to our current study. We 
currently do not have follow-up data of the patients after 
treatment and currently have not subclassified BCLC 
stage B HCC according to Bolondi’s subclassification 
because of limited patients in stage B. Further studies are 
needed to see whether serum PIVKA-II levels can help 
determine the best treatment option for heterogeneous 
patients, especially in BCLC stage B HCC patients 
according to Bolondi’s subclassification.
CONCLUSION
Our study can conclude that serum PIVKA-II levels can 
help to diagnose, differentiate between stages of BCLC, 
and determine the prognostic factors (tumor size and 
presence of portal venous thrombosis) in patients with 
HCC. 
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